Albireo, an Ipsen Company
Clinical trials sponsored by Albireo, an Ipsen Company, explained in plain language.
A biopharmaceutical company focused on liver diseases, now part of Ipsen.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug may help kids with rare liver disease avoid transplant Results expected Oct 2026 (estimated)
- New hope for kids with rare liver disease: long-term drug study launched Results expected Dec 2026 (estimated)
-
New drug may help kids with rare liver disease avoid transplant
Disease control OngoingThis study tests a drug called odevixibat in 180 children with biliary atresia, a rare liver disease. The goal is to see if the drug helps children stay alive without needing a liver transplant over the long term. Children who completed a previous study can join this open-label e…
Phase 3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for kids with rare liver disease: long-term drug study launched
Symptom relief OngoingThis study looks at the long-term safety and effectiveness of odevixibat in 70 people with Alagille syndrome, a rare genetic condition that affects the liver and other organs. The drug aims to reduce severe itching and improve bile flow. Participants who completed a prior 24-week…
Phase 3 • Sponsor: Albireo, an Ipsen Company • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC